Browsing Tag
Arcutis Biotherapeutics
4 posts
What the end of the Kowa partnership signals for Arcutis Biotherapeutics’ commercial control of ZORYVE
Arcutis Biotherapeutics ends its Kowa partnership and takes full control of ZORYVE promotion. Find out what this signals for adoption and strategy.
Toddlers get a breakthrough eczema treatment as FDA clears Arcutis’ ZORYVE cream 0.05%
Find out how Arcutis’ FDA-approved ZORYVE 0.05% cream is reshaping the pediatric eczema market and investor confidence in 2025.
FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis
In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the…
Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis
Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration’s (FDA) approval of…